A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Due Diligence Checklist for Early Stage Investors | ||||||||||||||||||||||||||
2 | www.seraf-investor.com | Anyone is free to use this Google Sheet. It is designed to be used in conjunction with our companion eBook. | If you want to learn more about angel investing, check out these other resources. | The Due Diligence Checklist for Early Stage Investors is designed as a quick reference guide to help steer you through the various aspects of diligence. By using this checklist, you can ensure that your process covers the major areas of diligence. The questions here are optimized for evaluation of very early stage technology companies; supplemental questions may be appropriate for use with later stage companies and life sciences companies. This Google Sheet offers suggested guidelines. It does not purport to be comprehensive, so use your judgement when conducting your due diligence. | |||||||||||||||||||||||
3 | Stones Unturned: An Investor's Guide to Due Diligence in Early Stage Companies | https://seraf-investor.com/compass | If you like this checklist, share this link! http://bit.ly/2lSfyFn | ||||||||||||||||||||||||
4 | Diligence Topic | Information Request | Tasks | Key Questions | |||||||||||||||||||||||
5 | Leadership Assessment | Resumes for key leadership team members | Review resumes | Does the CEO possess the experience and leadership abilities to succeed? | |||||||||||||||||||||||
6 | Professional references for key team members | Interview references (see interview guidelines) | Do they have skills for where they are going, as opposed to where they have been? | ||||||||||||||||||||||||
7 | Resumes and contact info for board members and advisors | Gather additional information from network as available (asking around, checking LinkedIn - anything to find blind reference checks) | Do the CEO and team have a proven track record? | ||||||||||||||||||||||||
8 | Assign team member(s) to spend time with CEO | Does the team possess the appropriate balance of experience and skill sets? | |||||||||||||||||||||||||
9 | Assess CEO and team for leadership, integrity, track record, required competencies | Are the board members and advisors suitable and committed? | |||||||||||||||||||||||||
10 | Assess suitability and commitment of board members and advisors | What key hires are needed to address gaps? | |||||||||||||||||||||||||
11 | |||||||||||||||||||||||||||
12 | Technology, IP and Product Roadmap | Descriptions of technology and product | Review information and meet with technical team | Is the technical team qualified and experienced? | |||||||||||||||||||||||
13 | Relevant technical publications | Assess critical technologies, tool choices, software architecture choices, scalability of solution | How strong are the technology and IP positions? | ||||||||||||||||||||||||
14 | Patents and patent applications | Assess IP defensibility | Is the product roadmap achievable? | ||||||||||||||||||||||||
15 | Related IP info (defense: Freedom to Operate (FTO)?, offense: enforceability?) | Conduct additional secondary research as needed | What are the remaining risks related to technology, IP and product roadmap? | ||||||||||||||||||||||||
16 | Product roadmap with key milestones | Conduct additional expert interviews if needed | Are their superior technologies on the near term horizon? | ||||||||||||||||||||||||
17 | Competing technologies and commercialization status | Assess remaining technical risk, IP defensibility, competitive technical position | |||||||||||||||||||||||||
18 | |||||||||||||||||||||||||||
19 | Regulatory Strategy | Regulatory strategy, if relevant | Review regulatory strategy | Is the regulatory strategy well thought through and feasible? | |||||||||||||||||||||||
20 | Status of dialogue with regulatory authorities and/or consultants, copies of relevant communications | Interview regulatory experts | Are the company's financial resources sufficient to implement the regulatory plan? | ||||||||||||||||||||||||
21 | Assess comparable regulatory pathways for other products as appropriate | Are assumptions about partners/acquirors' roles in the regulatory plan reasonable? | |||||||||||||||||||||||||
22 | Assess regulatory climate | What are the remaining regulatory risks? | |||||||||||||||||||||||||
23 | |||||||||||||||||||||||||||
24 | Customer Need and Go-to-Market Plan | Go-to-Market plan with key milestones and granular detail on sales approach | Review information and meet with marketing and sales team | Is the Go-to-Market plan reasonable? | |||||||||||||||||||||||
25 | Partner identification and relationship status | Interview customers, partners, prospects as appropriate | Is the sales pipeline adequate, and are key metrics for adoption rate, conversion rates, etc. conservative? | ||||||||||||||||||||||||
26 | Sales pipeline by stage, factored to be truly realistic and achievable | Gather information on industry comparables as appropriate | Do customers confirm the need and likely adoption rates? | ||||||||||||||||||||||||
27 | Any current marketing, joint venture, distribution agreements | Collaborate with financial team to assess revenue and pricing model | Beyond verifying some demand, do we understand the customers buying priorities? Is this product/service a "Nice to Have" or a "Need to Have"? | ||||||||||||||||||||||||
28 | Customer, prospect, and partner references (see guidelines for interviewing customers) | What are the major risks in marketing awareness, customer adoption rates and sales cycle? | |||||||||||||||||||||||||
29 | |||||||||||||||||||||||||||
30 | Uniqueness and Competition | List of current and prospective competitors | Gather additional competitive intelligence as needed | Is the company well positioned with respect to current and likely future competitors? | |||||||||||||||||||||||
31 | Competitive analysis including market share, relative strengths and weaknesses | Assess competitive environment, competitor positions, barriers to entry | Is the founding team well-informed about their market and industry? Do they have a good competitive sense, or are they unaware of key issues | ||||||||||||||||||||||||
32 | What are the major risks in marketing awareness, customer adoption rates and sales cycle? | ||||||||||||||||||||||||||
33 | |||||||||||||||||||||||||||
34 | Market Size and Market Opportunity | Market estimates from the company, properly segmented down to a reasonable addressable market segment | Gather additional market data as needed | Are the top-down and bottoms-up market estimates consistent and attractive? | |||||||||||||||||||||||
35 | Published market data and industry reports by segment, industry vertical, and/or geography as relevant | Interview industry experts as needed | Are the market share projections reasonable? | ||||||||||||||||||||||||
36 | Assess market opportunity and product/market fit | What are the remaining risks in market development? | |||||||||||||||||||||||||
37 | Assess company's market estimates and share assumptions | ||||||||||||||||||||||||||
38 | |||||||||||||||||||||||||||
39 | Financial Projections and Funding Strategy | Current balance sheet | Assess balance sheet | Does the balance sheet make sense, and are there any showstopper issues? | |||||||||||||||||||||||
40 | Historical financials | Assess historical and projected financials including revenue model, assumptions, use of funds | Are the financial projections reasonable and conservative in light of past performance? | ||||||||||||||||||||||||
41 | Model of projected financials with sensitivity analyses on key assumptions | Conduct sensitivity analyses on key assumptions | What are the implications of variances in key assumptions? | ||||||||||||||||||||||||
42 | Fundraising history | Assess future financing needs | Is the future financing risk manageable? | ||||||||||||||||||||||||
43 | Use of funds - past and projected | What are remaining financial risks? | |||||||||||||||||||||||||
44 | Future financing needs and assumptions | Are the assumptions about scaling expense (e.g. G&A, etc.) reasonable, or is the model unrealistic? | |||||||||||||||||||||||||
45 | |||||||||||||||||||||||||||
46 | Exit Strategy | Exit strategy | Discuss exit scenarios with CEO | Is there alignment with the CEO and team on exit goals? | |||||||||||||||||||||||
47 | Likely acquirers and comparables | Assess realism of exit strategy | Is the exit strategy reasonable? | ||||||||||||||||||||||||
48 | Develop reasonable exit scenarios | What exit multiples can be predicted under representative scenarios? | |||||||||||||||||||||||||
49 | Model exit multiples under representative scenarios | Does the CEO know people in the industry? Is she a networker who will make the relationships and do the thought-leadership necessary to get a buyer interested? | |||||||||||||||||||||||||
50 | |||||||||||||||||||||||||||
51 | Company Structure, Deal Terms | Documents of incorporation | Confirm legal entity (C Corp, state of incorporation) | What changes to legal structure need to be undertaken? | |||||||||||||||||||||||
52 | Capitalization Table | Review existing investors, classes of stock | Are there any showstopper issues (pre-existing agreements, complex shareholder structure, high vendor payables, loans to management, informal promises or undocumented issuances of stock?) | ||||||||||||||||||||||||
53 | Proposed deal terms | Assess deal terms | What terms should be changed/negotiated (e.g., valuation, employee stock option pool, etc.?) | ||||||||||||||||||||||||
54 | |||||||||||||||||||||||||||
55 | |||||||||||||||||||||||||||
56 | www.seraf-investor.com | This Due Diligence Checklist is brought to you by Seraf, which is committed to increasing the professionalism of early-stage investing. Seraf is a web-based portfolio management tool for investors in early stage companies. Seraf’s intuitive dashboard gives investors the power to organize all of their early stage activities in one online workspace. To learn more, visit Seraf-Investor.com. | If you like this checklist, share this link! http://bit.ly/2lSfyFn | ||||||||||||||||||||||||
57 | |||||||||||||||||||||||||||
58 | |||||||||||||||||||||||||||
59 | |||||||||||||||||||||||||||
60 | |||||||||||||||||||||||||||
61 | |||||||||||||||||||||||||||
62 | |||||||||||||||||||||||||||
63 | |||||||||||||||||||||||||||
64 | |||||||||||||||||||||||||||
65 | |||||||||||||||||||||||||||
66 | |||||||||||||||||||||||||||
67 | |||||||||||||||||||||||||||
68 | |||||||||||||||||||||||||||
69 | |||||||||||||||||||||||||||
70 | |||||||||||||||||||||||||||
71 | |||||||||||||||||||||||||||
72 | |||||||||||||||||||||||||||
73 | |||||||||||||||||||||||||||
74 | |||||||||||||||||||||||||||
75 | |||||||||||||||||||||||||||
76 | |||||||||||||||||||||||||||
77 | |||||||||||||||||||||||||||
78 | |||||||||||||||||||||||||||
79 | |||||||||||||||||||||||||||
80 | |||||||||||||||||||||||||||
81 | |||||||||||||||||||||||||||
82 | |||||||||||||||||||||||||||
83 | |||||||||||||||||||||||||||
84 | |||||||||||||||||||||||||||
85 | |||||||||||||||||||||||||||
86 | |||||||||||||||||||||||||||
87 | |||||||||||||||||||||||||||
88 | |||||||||||||||||||||||||||
89 | |||||||||||||||||||||||||||
90 | |||||||||||||||||||||||||||
91 | |||||||||||||||||||||||||||
92 | |||||||||||||||||||||||||||
93 | |||||||||||||||||||||||||||
94 | |||||||||||||||||||||||||||
95 | |||||||||||||||||||||||||||
96 | |||||||||||||||||||||||||||
97 | |||||||||||||||||||||||||||
98 | |||||||||||||||||||||||||||
99 | |||||||||||||||||||||||||||
100 |